193 related articles for article (PubMed ID: 29562252)
1. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab.
Masoud S; McAdoo SP; Bedi R; Cairns TD; Lightstone L
Rheumatology (Oxford); 2018 Jul; 57(7):1156-1161. PubMed ID: 29562252
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.
McAdoo SP; Bedi R; Tarzi R; Griffith M; Pusey CD; Cairns TD
Rheumatology (Oxford); 2016 Aug; 55(8):1437-42. PubMed ID: 27094598
[TBL] [Abstract][Full Text] [Related]
3. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
4. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ.
Lei L; Muhammad S; Al-Obaidi M; Sebire N; Cheng IL; Eleftheriou D; Brogan P
Pediatr Rheumatol Online J; 2018 Sep; 16(1):61. PubMed ID: 30257684
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Kraaij T; Arends EJ; van Dam LS; Kamerling SWA; van Daele PLA; Bredewold OW; Ray A; Bakker JA; Scherer HU; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1474-1483. PubMed ID: 32591783
[TBL] [Abstract][Full Text] [Related]
6. Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.
Hassan SU; Md Yusof MY; Emery P; Dass S; Vital EM
Front Med (Lausanne); 2020; 7():498. PubMed ID: 32984378
[No Abstract] [Full Text] [Related]
7. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
8. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
[TBL] [Abstract][Full Text] [Related]
10. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
[TBL] [Abstract][Full Text] [Related]
11. Rituximab Biosimilar BCD020 Shows Superior Efficacy above Conventional Non-Biologics Treatment in Pediatric Lupus Nephritis: The Data of Retrospective Cohort Study.
Kostik M; Kalashnikova E; Rinat R; Isupova E; Gaidar E; Soloviev AA; Masalova V; Snegireva L; Kornishina T; Abramova N; Suspitsin E; Sorokina L; Kaneva M; Dubko MF; Lubimova N; Kuchuinskaya E; Kalashnikova O; Chasnyk V
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239173
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Arnold J; Dass S; Twigg S; Jones CH; Rhodes B; Hewins P; Chakravorty M; Courtney P; Ehrenstein M; Md Yusof MY; Vital EM
Rheumatology (Oxford); 2022 Nov; 61(12):4905-4909. PubMed ID: 35266512
[TBL] [Abstract][Full Text] [Related]
13. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
Looney RJ; Anolik JH; Campbell D; Felgar RE; Young F; Arend LJ; Sloand JA; Rosenblatt J; Sanz I
Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the treatment of systemic lupus erythematosus.
Robak E; Robak T
Curr Drug Targets; 2009 Jan; 10(1):26-37. PubMed ID: 19149533
[TBL] [Abstract][Full Text] [Related]
16. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
17. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
18. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
[TBL] [Abstract][Full Text] [Related]
19. First case report of using Ofatumumab in kidney transplantation AB0 incompatible.
Mancianti N; Monaci G; Rollo F; Buracchi P; Guarnieri A; Di Luca M; Martello M; Garosi G
G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207227
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.
Iwata S; Saito K; Hirata S; Ohkubo N; Nakayamada S; Nakano K; Hanami K; Kubo S; Miyagawa I; Yoshikawa M; Miyazaki Y; Yoshinari H; Tanaka Y
Lupus; 2018 Apr; 27(5):802-811. PubMed ID: 29308726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
